Literature DB >> 23943791

A GAA repeat expansion reporter model of Friedreich's ataxia recapitulates the genomic context and allows rapid screening of therapeutic compounds.

Michele M P Lufino1, Ana M Silva, Andrea H Németh, Javier Alegre-Abarrategui, Angela J Russell, Richard Wade-Martins.   

Abstract

Friedreich's ataxia (FRDA) is caused by large GAA expansions in intron 1 of the frataxin gene (FXN), which lead to reduced FXN expression through a mechanism not fully understood. Understanding such mechanism is essential for the identification of novel therapies for FRDA and this can be accelerated by the development of cell models which recapitulate the genomic context of the FXN locus and allow direct comparison of normal and expanded FXN loci with rapid detection of frataxin levels. Here we describe the development of the first GAA-expanded FXN genomic DNA reporter model of FRDA. We modified BAC vectors carrying the whole FXN genomic DNA locus by inserting the luciferase gene in exon 5a of the FXN gene (pBAC-FXN-Luc) and replacing the six GAA repeats present in the vector with an ∼310 GAA repeat expansion (pBAC-FXN-GAA-Luc). We generated human clonal cell lines carrying the two vectors using site-specific integration to allow direct comparison of normal and expanded FXN loci. We demonstrate that the presence of expanded GAA repeats recapitulates the epigenetic modifications and repression of gene expression seen in FRDA. We applied the GAA-expanded reporter model to the screening of a library of novel small molecules and identified one molecule which up-regulates FXN expression in FRDA patient primary cells and restores normal histone acetylation around the GAA repeats. These results suggest the potential use of genomic reporter cell models for the study of FRDA and the identification of novel therapies, combining physiologically relevant expression with the advantages of quantitative reporter gene expression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23943791      PMCID: PMC3842177          DOI: 10.1093/hmg/ddt370

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  62 in total

1.  Rational selection of small molecules that increase transcription through the GAA repeats found in Friedreich's ataxia.

Authors:  LaKechia Grant; Jun Sun; Hongzhi Xu; S H Subramony; Jonathan B Chaires; Michael D Hebert
Journal:  FEBS Lett       Date:  2006-09-15       Impact factor: 4.124

2.  Infectious delivery and expression of a 135 kb human FRDA genomic DNA locus complements Friedreich's ataxia deficiency in human cells.

Authors:  Silvia Gomez-Sebastian; Alfredo Gimenez-Cassina; Javier Diaz-Nido; Filip Lim; Richard Wade-Martins
Journal:  Mol Ther       Date:  2007-02       Impact factor: 11.454

3.  Progressive GAA.TTC repeat expansion in human cell lines.

Authors:  Scott Ditch; Mimi C Sammarco; Ayan Banerjee; Ed Grabczyk
Journal:  PLoS Genet       Date:  2009-10-30       Impact factor: 5.917

4.  Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3.

Authors:  Ping K Chan; Raul Torres; Cihangir Yandim; Pui P Law; Sanjay Khadayate; Marta Mauri; Crina Grosan; Nadine Chapman-Rothe; Paola Giunti; Mark Pook; Richard Festenstein
Journal:  Hum Mol Genet       Date:  2013-03-07       Impact factor: 6.150

5.  Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues.

Authors:  Alain Martelli; Marie Wattenhofer-Donzé; Stéphane Schmucker; Samuel Bouvet; Laurence Reutenauer; Hélène Puccio
Journal:  Hum Mol Genet       Date:  2007-06-27       Impact factor: 6.150

6.  The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins.

Authors:  Arnulf H Koeppen; Susan C Michael; Mitchell D Knutson; David J Haile; Jiang Qian; Sonia Levi; Paolo Santambrogio; Michael D Garrick; Jacques B Lamarche
Journal:  Acta Neuropathol       Date:  2007-04-11       Impact factor: 17.088

7.  The dorsal root ganglion in Friedreich's ataxia.

Authors:  Arnulf H Koeppen; Jennifer A Morral; Ashley N Davis; Jiang Qian; Simone V Petrocine; Mitchell D Knutson; Walter M Gibson; Matthew J Cusack; Danhong Li
Journal:  Acta Neuropathol       Date:  2009-08-30       Impact factor: 17.088

8.  An S/MAR-based infectious episomal genomic DNA expression vector provides long-term regulated functional complementation of LDLR deficiency.

Authors:  Michele M P Lufino; Roberto Manservigi; Richard Wade-Martins
Journal:  Nucleic Acids Res       Date:  2007-08-02       Impact factor: 16.971

9.  Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia.

Authors:  Eriko Greene; Lata Mahishi; Ali Entezam; Daman Kumari; Karen Usdin
Journal:  Nucleic Acids Res       Date:  2007-05-03       Impact factor: 16.971

10.  A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro.

Authors:  Ed Grabczyk; Miriam Mancuso; Mimi C Sammarco
Journal:  Nucleic Acids Res       Date:  2007-08-09       Impact factor: 16.971

View more
  14 in total

1.  Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.

Authors:  Matteo Gianella-Borradori; Ivy Christou; Carole J R Bataille; Rebecca L Cross; Graham M Wynne; David R Greaves; Angela J Russell
Journal:  Bioorg Med Chem       Date:  2014-11-08       Impact factor: 3.641

Review 2.  Pharmacological treatments for Friedreich ataxia.

Authors:  Mary Kearney; Richard W Orrell; Michael Fahey; Ruth Brassington; Massimo Pandolfo
Journal:  Cochrane Database Syst Rev       Date:  2016-08-30

3.  Alleviating GAA Repeat Induced Transcriptional Silencing of the Friedreich's Ataxia Gene During Somatic Cell Reprogramming.

Authors:  Urszula Polak; Yanjie Li; Jill Sergesketter Butler; Marek Napierala
Journal:  Stem Cells Dev       Date:  2016-10-17       Impact factor: 3.272

4.  Synthetic transcription elongation factors license transcription across repressive chromatin.

Authors:  Graham S Erwin; Matthew P Grieshop; Asfa Ali; Jun Qi; Matthew Lawlor; Deepak Kumar; Istaq Ahmad; Anna McNally; Natalia Teider; Katie Worringer; Rajeev Sivasankaran; Deeba N Syed; Asuka Eguchi; Md Ashraf; Justin Jeffery; Mousheng Xu; Paul M C Park; Hasan Mukhtar; Achal K Srivastava; Mohammed Faruq; James E Bradner; Aseem Z Ansari
Journal:  Science       Date:  2017-11-30       Impact factor: 47.728

5.  Expanded GAA repeats impair FXN gene expression and reposition the FXN locus to the nuclear lamina in single cells.

Authors:  Ana M Silva; Jill M Brown; Veronica J Buckle; Richard Wade-Martins; Michele M P Lufino
Journal:  Hum Mol Genet       Date:  2015-03-26       Impact factor: 6.150

6.  R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome.

Authors:  Matthias Groh; Michele M P Lufino; Richard Wade-Martins; Natalia Gromak
Journal:  PLoS Genet       Date:  2014-05-01       Impact factor: 5.917

Review 7.  Neurodegenerative diseases in a dish: the promise of iPSC technology in disease modeling and therapeutic discovery.

Authors:  Y Z Xie; R X Zhang
Journal:  Neurol Sci       Date:  2014-10-30       Impact factor: 3.307

8.  Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor.

Authors:  Yogesh K Chutake; Christina C Lam; Whitney N Costello; Michael P Anderson; Sanjay I Bidichandani
Journal:  Nucleic Acids Res       Date:  2016-02-20       Impact factor: 16.971

9.  Generation and characterisation of Friedreich ataxia YG8R mouse fibroblast and neural stem cell models.

Authors:  Chiranjeevi Sandi; Madhavi Sandi; Harvinder Jassal; Vahid Ezzatizadeh; Sara Anjomani-Virmouni; Sahar Al-Mahdawi; Mark A Pook
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

Review 10.  Epigenetic-based therapies for Friedreich ataxia.

Authors:  Chiranjeevi Sandi; Madhavi Sandi; Sara Anjomani Virmouni; Sahar Al-Mahdawi; Mark A Pook
Journal:  Front Genet       Date:  2014-06-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.